Patents by Inventor Franck Perez
Franck Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101616Abstract: A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Franck Perez, Zelia Gouveia, Sebastian Amigorena, Gaelle Boncompain
-
Publication number: 20240084354Abstract: The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein: said gene encoding the hook protein is under the control of a first transcription-activating signal, said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal, said hook protein is fused to a cellular compartment-retention peptide, and said protein of interest is fused to a hook protein-binding domain It also related to vectors comprising the polynucleotide, cells comprising the polynucleotide or the vector and compositions comprising the same.Type: ApplicationFiled: November 15, 2021Publication date: March 14, 2024Applicants: HONING BIOSCIENCES, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Franck PEREZ, Zelia GOUVEIA
-
Publication number: 20240018197Abstract: A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.Type: ApplicationFiled: September 11, 2023Publication date: January 18, 2024Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Franck PEREZ, Zelia GOUVEIA, Gaelle BONCOMPAIN
-
Patent number: 11866484Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: March 3, 2021Date of Patent: January 9, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Publication number: 20230302050Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.Type: ApplicationFiled: May 20, 2021Publication date: September 28, 2023Applicants: Institut Curie, Centre National de la Recherche Scientifique, The University of Zurich, Honing BiosciencesInventors: Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia
-
Publication number: 20230183675Abstract: The present invention relates to the identification of a fully humanized single domain antibody scaffold as well as its use in generating synthetic single domain antibodies. The invention further relates to antigen-binding proteins comprising said single domain antibody scaffold and their use in therapy.Type: ApplicationFiled: May 20, 2021Publication date: June 15, 2023Applicants: Institut Curie, Centre National de la Recherche ScientifiqueInventors: Franck Perez, Sandrine Moutel
-
Publication number: 20220162266Abstract: The present invention relates to a mutant polypeptide comprising the amino acid sequence of the ectodomain of glycoprotein G of a vesicular stomatitis vims (VSV) strain, wherein said ectodomain comprises the amino acid sequence as set forth in SEQ ID NO: 2 or a sequence having at least 50% of identity with the amino acid sequence as set forth in SEQ ID NO: 2, with at least one substitution of an amino acid residue selected from the group consisting of: a) any amino acid residue located from position 421 to position 429 and any amino acid residue located from position 17 to position 25 of SEQ ID NO:2; or b) any amino acid residue located from a position equivalent to position 421 to a position equivalent to position 429 of SEQ ID NO: 2 and any amino acid residue located from a position equivalent to position 17 to a position equivalent to position 25 of SEQ ID NO: 2, after optimal global alignment with SEQ ID NO:2.Type: ApplicationFiled: March 16, 2020Publication date: May 26, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SACLAYInventors: Aurélie ALBERTINI, Hélène RAUX, Yves GAUDIN, Franck PEREZ
-
Publication number: 20210347855Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: ApplicationFiled: March 3, 2021Publication date: November 11, 2021Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Patent number: 11162951Abstract: Fluorescent labeling of proteins. In particular, membrane-impermeant fluorogenic chromophores being capable of binding reversibly a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labeling biological molecules of interest, preferably proteins of interest. Especially, 4-hydroxybenzylidene-rhodanine (HBR) analogs of formula (II) as membrane-impermeant fluorogenic chromophores.Type: GrantFiled: May 18, 2018Date of Patent: November 2, 2021Assignees: PARIS SCIENCES ET LETTRES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, SORBONNE UNIVERSITEInventors: Arnaud Gautier, Ludovic Jullien, Chenge Li, Franck Perez
-
Patent number: 11014977Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: June 25, 2018Date of Patent: May 25, 2021Assignees: INSERM (Institut National de al Santé et de la Recherche Médicale), Institut Curie, Université Paus Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Publication number: 20210107951Abstract: Disclosed are peptides, hosts expressing such peptides and a process for producing and screening such peptides or hosts. Also disclosed is use of the peptide or host expressing such peptide in the detection of disease, to a method for constructing a library of hosts, in particular of phages expressing peptides. Also disclosed is a library of hosts expressing peptides and its use for example for detecting molecules and/or cells in a sample, in the treatment of disease. These find application in the therapeutic and diagnostic medical technical fields.Type: ApplicationFiled: March 13, 2018Publication date: April 15, 2021Inventors: Thomas MURARASU, Franck PEREZ, Ludger JOHANNES
-
Patent number: 10968281Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.Type: GrantFiled: October 13, 2017Date of Patent: April 6, 2021Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALEInventors: Elodie Segura, Sebastian Amigorena, Franck Perez, Sandrine Moutel
-
Publication number: 20210009653Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: ApplicationFiled: July 17, 2020Publication date: January 14, 2021Inventors: Sophie AGAUGUE, Lorenzo TIBALDI, Klervi EVEN-DESRUMAUX, Dmitry TRUBETSKOY, Franck PEREZ, Sebastian AMIGORENA, Cécile BAUCHE
-
Publication number: 20200331975Abstract: The present invention relates to a chimeric antigen receptor comprising: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, anda hook binding domain.The present invention also relates to a vector system comprising one or more vector comprising: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably comprising a streptavidin core; wherein said nucleic acids are located on the same or on different vectors; The invention also encompasses lentiviral vector particles system, host cell and kit comprising said nucleic acids or vector system. The invention also relates to lentiviral vector particles system, host cell and kit as herein disclosed for their use as a medicament, notably for immunotherapy.Type: ApplicationFiled: October 22, 2018Publication date: October 22, 2020Inventors: Franck Perez, Zelia Gouveia, Sebastian Amigorena, Gaelle Boncompain
-
Publication number: 20200283485Abstract: The present invention relates to a hook fusion protein comprising a hook domain and at least one cytoplasmic carboxy terminal endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. The present invention also relates to a nucleic acid system for intracellular targeting control comprising a nucleic acid encoding a hook fusion protein as herein disclosed, and a nucleic acid encoding a target fusion protein comprising a hook-binding domain; wherein said target fusion protein in a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. The invention also encompasses a vector system, viral particle system, host cell and kit comprising said nucleic acids.Type: ApplicationFiled: October 22, 2018Publication date: September 10, 2020Inventors: Franck Perez, Zelia Gouveia, Gaelle Boncompain
-
Patent number: 10752668Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: GrantFiled: July 24, 2015Date of Patent: August 25, 2020Assignees: Theravectys, Institut Curie, Centre National de la Recherche Scientifique, Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Sophie Agaugue, Lorenzo Tibaldi, Klervi Even-Desrumaux, Dmitry Trubetskoy, Franck Perez, Sebastian Amigorena, Cécile Bauche
-
Publication number: 20200124611Abstract: Fluorescent labeling of proteins. In particular, membrane-impermeant fluorogenic chromophores being capable of binding reversibly a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labeling biological molecules of interest, preferably proteins of interest. Especially, 4-hydroxybenzylidene-rhodanine (HBR) analogs of formula (II) as membrane-impermeant fluorogenic chromophores.Type: ApplicationFiled: May 18, 2018Publication date: April 23, 2020Applicants: PARIS SCIENCES ET LETTRES - QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, SORBONNE UNIVERSITEInventors: Arnaud GAUTIER, Ludovic JULLIEN, Chenge LI, Franck PEREZ
-
Publication number: 20190367635Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.Type: ApplicationFiled: October 13, 2017Publication date: December 5, 2019Inventors: ELODIE SEGURA, SEBASTIAN AMIGORENA, FRANCK PEREZ, SANDRINE MOUTEL
-
Publication number: 20180327481Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: ApplicationFiled: June 25, 2018Publication date: November 15, 2018Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Patent number: 10030068Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: June 30, 2017Date of Patent: July 24, 2018Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Curie, Universite Paul Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez